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S284 Poster Session Iaggressive chemotherapy and radiotherapy on future fertility are
being increasingly realized in males. To counteract such deleteri-
ous effects, we initiated a formal fertility preservation program in
2007 to increase access to sperm cryopreservation (SCP) services
at our institution. Here we analyze our program’s utility and pa-
tient data to provide insight into fertility preservation prior to
SCT.
Methods: An IRB-approved chart review was conducted on all male
pediatric patients older than 13 years who underwent SCT between
January 2008 and June 2010 at our institution. Patients given a fertil-
ity preservation consult were identified, and the semen parameters of
those subsequently banking sperm were obtained.
Results:During the study interval, 22 male pediatric patients met
our study criteria, of which there were 19 allo-transplants and 3
auto-transplants. 8/22 (36%) patients were given fertility preserva-
tion consults and 6/22 (27%) proceeded to SCP, a consult success
rate of 75% (Table 1). 6/13 (38%) patients with planned radio-
therapy were consulted, compared to 2/9 (22%) patients with no
planned radiotherapy. Of the 6 patients banking sperm, 3 banked
prior to chemotherapy while 3 banked after. The average semen
parameters of patients banking before chemo vs after chemo-
therapy were as follows: Volume 2.50 vs 1.50 ml; Concentration
30.7 vs 30.6 million/ml; Motility 36.7% vs 21.3%; Normal
Morphology 9.7% vs 3.5%. Thus, while patients who banked
after chemotherapy had sub-fertile semen parameters, their bulk
semen parameters were still adequate for cryopreservation. All
bulk semen parameters tended to improve as age at banking
increased.
Conclusions:The high fertility preservation consult success rate in-
dicates a large desire to preserve fertility in patients planning SCT.
While bulk semen parameters were adequate for cryopreservation
in patients after treatment, DNA damage resulting from chemother-
apy was not assessed. Although cryopreservation of some sperm is
preferred over none, ample literature supports the notion that che-
motherapy has a deleterious effect on fertilization and embryo devel-
opment outcomes. Thus, every effort should be made to
cryopreserve sperm prior to chemotherapy and radiation. Finally,
further initiatives are required to extend the opportunity of fertility
preservation to all SCT patients.
Table 1. Demographic Comparison of All SCT Patients vs.
Consulted Patients
All Patients (N 5 22) Consulted Patients (N 5 8)Year
2008 10 4
2009 9 3
2010 3 1Transplant Type
Allogenic 19 7
Autologous 3 1Ethnicity
Caucasian 12 5
African American 4 1
Hispanic 5 2
Other 1 0219
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Hospital readmissions increase healthcare cost and are a target
of ways to improve cost and quality of medical care. Patients (pts)
who undergo allogeneic hematopoietic progenitor cell transplant
require a high level of care and are often readmitted. Thirty-day
hospital readmissions following allogeneic HPCT, however, are
associated with poor survival. In this retrospective review, weevaluated our 30-day readmissions for allogeneic HPCT occur-
ring in 2010 at our institution. The analysis included pts who
were not only transplanted in 2010 but also those who had
been previously transplanted (ranging from 1994-2010), and later
hospitalized again in 2010 and subsequently readmitted within
30 days.
There were 83 total readmissions for allogeneic transplant pts
within 30 days of a prior hospitalization in 2010. Only 47 pts,
however, accounted for these readmissions and 19 (23%) pts
were admitted multiple times (range 2-5 times), accounting for
55 (66%) of the readmissions. Initial diagnoses for pts admitted
more than once included: 7 refractory NHL, 4 AML, 3 ALL, 2
MDS, 2 AA and 1 CML. Donor type included 4 UCB, 5 MUD
and 10 MSD. Fifty-two percent (n 5 10) had a CIBMTR trans-
plant co-morbidity index score of .2. Fifty-three (64%) of the
30d readmissions after allogeneic HPCT were due to infection
or unexplained fever, followed by 9 (11%) for symptoms related
to GVHD, 7 (8%) due to cardiac complications (CHF, arrhyth-
mias), and 14 (17%) others related to symptom management
(pain, nausea/vomiting, diarrhea not related to infection or
GVHD). Looking specifically at reasons for subsequent repeated
readmissions demonstrated a similar distribution with the majority
of re-hospitalizations being for infection or unexplained fever, fol-
lowed by symptom management, cardiac complications, and
GVHD. There were 13 deaths, all related to infection or compli-
cations from GVHD. Median time to death after readmission was
27 days (range, 0 to 96).
Readmissions for allogeneic HPCT are associated with worse
survival. In this retrospective review we have found that the ma-
jority of readmissions were from pts admitted multiple times.
About half of these pts were identified as having higher co-
morbidity index scores. Further prospective studies of readmission
trends in allogeneic transplant and identification of high risk pts
who may be susceptible to multiple readmissions may help de-
crease readmission rates, transplant outcomes, and improve overall
quality of care.220
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Background: The association between venous thromboembolism
(VTE) and hematologic malignancy is well established. However,
VTE after allogeneic hematopoietic cell transplantation (HCT) is
not well characterized. The management is not standardized and
varies between hematologists.
Methods: A total of 260 patients underwent allogeneic HCT at
the University of Iowa between 2004 and 2009. Patient’s data
were retrospectively abstracted from the electronic medical record
and bone marrow transplant database. We report the incidence,
characteristics, management and outcome of VTE following
allotransplant.
Results: Of 260 patients who underwent allogeneic HCT, 35
(13.5%) developed VTE events. The median time from transplant
to VTE diagnosis was 121 days (-3 to 1853 d). Twenty-two pa-
tients (63%) developed VTE during the first six months post allo-
transplant. Sixteen patients (47%) had central venous catheter
related VTE. At VTE diagnosis, six patients (17%) had active he-
matologic malignancy and 18 patients (51%) had active GVHD ($
grade III). The median platelet count at VTE diagnosis was 65
(5-676) x 106/mm3. Twenty-five patients (71%) received systemic
anticoagulation (17 heparin products VS 8 heparin followed by
warfarin). Eight of 25 patients (32%) who had anticoagulation
treatment received therapeutic dose of anticoagulant whereas 17
patients had prophylactic dose. Among 10 patients who did not
receive systemic anticoagulation treatment either due to clinical ac-
tive bleeding or severe thrombocytopenia, two underwent inferior
vena cava filter placement. Eight patients (32%) had hemorrhagic
complications during anticoagulation. The median anticoagulation
